Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
18 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 19
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
APAC
🇮🇳 IndiaOfficialSelected classification, commercial CT permissions, licences and PV provisions; read with the separate 2026 amendments. Not a fully current consolidated code.2019; consolidated through 2022Latest observed: 2019; consolidated through 2022
🇮🇳 IndiaOfficialDated launch, selection criteria, 384 medicines and care levels. NLEM does not itself establish scheme benefits or procurement.2022-09-13Latest observed: 2022-09-13
🇮🇳 IndiaOfficialSelected user-department, topic, TAC/Board and implementation sections. No universal drug threshold or product coverage is established.2022Latest observed: 2022
🇮🇳 IndiaOfficialSelected FAQ on contracts, settings, exclusions, limits and product choice. Individual coverage requires the actual policy.Includes guidance on the 2024-05-29 Master CircularLatest observed: Includes guidance on the 2024-05-29 Master Circular
🇮🇳 IndiaOfficialPhysical page 13: essential generic availability, procurement, quality, warehouses and DVDMS. Planning targets are not actual stock evidence.FY2026–27Latest observed: FY2026–27
🇮🇳 IndiaOfficialHistorical financing context: OOPE 43.4% in 2022–23. Not a current patient charge or insurance benefit.2026-05-27 release; data for 2022–23Latest observed: 2026-05-27 release; data for 2022–23
🇮🇳 IndiaOfficialSelected classification and Q79–96 on evidence, waiver, Phase IV and permission. Official explanation, read with rules and subsequent 2026 instruments.2025Latest observed: 2025
🇮🇳 IndiaOfficialFull one-page advisory: actual marketing starts timelines; consolidated reporting retains separate data. Not a new marketing approval.2026-04-21Latest observed: 2026-04-21
🇮🇳 IndiaOfficialSix specified jurisdictions and five product categories; waiver conditions remain applicable.2024-08-07Latest observed: 2024-08-07
🇮🇳 IndiaOfficialFull one-page clarification: relevant import-marketing applications undergo comprehensive IND evaluation; Indian GCT participation is not automatic waiver.2026-08-10Latest observed: 2026-08-10
🇮🇳 India
OfficialEnglish operative text, pages 6–9: test-manufacturing and prior-intimation amendments; not a waiver of commercial permission.2026-01-20; commencement after 45 days from publicationLatest observed: 2026-01-20; commencement after 45 days from publication
🇮🇳 India
OfficialRule 31 second proviso: residual shelf life at import; one-year rule and discretionary 60% provision for biological drugs/radiopharmaceuticals.Notification 2026-10-16; Gazette 2026-10-28; effective on publicationLatest observed: Notification 2026-10-16; Gazette 2026-10-28; effective on publication
🇮🇳 India
OfficialEnglish pages 5–7, especially paragraph 15: other-existing-manufacturer same-drug launch exception, 12 months, Form-IA within one month and retained price cap.2026-06-30; effective on publicationLatest observed: 2026-06-30; effective on publication
🇮🇳 IndiaOfficialSelected definitions and paragraphs 4–5, 13–16, 19–21, 32 and Schedule I; read paragraph 15 with the separate June 2026 amendment. Not all later orders or exemptions.2013; consolidated amendments through 2023-05-25Latest observed: 2013; consolidated amendments through 2023-05-25
🇮🇳 IndiaOfficialCurrent dated explanation of scheduled/non-scheduled monitoring and WPI. No claim that all current NPPA product orders were reviewed.2026-08-07Latest observed: 2026-08-07
🇮🇳 IndiaOfficialSelected package, inpatient/day-care, preauthorisation and claim workflow architecture only. Not current 2026 rates, package counts or state adaptations.September 2020 document; official state-host copyLatest observed: September 2020 document; official state-host copy
🇮🇳 IndiaOfficialEligible hospital treatment, the age-70 extension and public free-drug support. No proof of individual eligibility, drug stock or local package details.2026-08-07Latest observed: 2026-08-07
🇮🇳 IndiaOfficialAchievements pages 85–86 and the parliamentary answer support beneficiary/formulary/dispensary/ALC architecture. Full January 2026 procurement policy remains unverified; no old monetary threshold is asserted as current.2025 achievements (January 2026 host); answer 2025-08-08Latest observed: 2025 achievements (January 2026 host); answer 2025-08-08
🇮🇳 IndiaOfficialAchievements pages 85–86 and the parliamentary answer support beneficiary/formulary/dispensary/ALC architecture. Full January 2026 procurement policy remains unverified; no old monetary threshold is asserted as current.2025 achievements (January 2026 host); answer 2025-08-08Latest observed: 2025 achievements (January 2026 host); answer 2025-08-08
For education only — not regulatory, pricing or legal advice.